Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Authors
Keywords
-
Journal
BIODRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-11
DOI
10.1007/s40259-020-00425-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
- (2019) Ilke Tunali et al. LUNG CANCER
- Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties
- (2019) Roland G Stein et al. CANCER RESEARCH
- Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
- (2019) Yada Kanjanapan et al. CANCER
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
- (2019) C G Kim et al. ANNALS OF ONCOLOGY
- Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report
- (2019) Maiko Asai et al. Immunotherapy
- Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment
- (2019) Kentaro Masuhiro et al. Journal of Thoracic Oncology
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
- (2019) Robert Haddad et al. CANCER
- 1282PDissociated responses in patients with metastatic solid tumours treated with immunotherapy
- (2019) P Vaflard et al. ANNALS OF ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer
- (2019) Mohammadhadi Khorrami et al. Cancer Immunology Research
- Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
- (2019) Jong Yeob Kim et al. Cancers
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Pseudoprogression and hyperprogression after checkpoint blockade
- (2018) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- (2018) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
- (2018) Song Ee Park et al. Journal of Thoracic Oncology
- Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Sharyn I. Katz et al. Journal of Thoracic Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy
- (2018) Jonathan S. Kurman et al. Journal of Thoracic Disease
- Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
- (2018) Shisuo Du et al. OncoImmunology
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
- (2018) Jenny H. Lee et al. JAMA Oncology
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
- (2018) Ignacio Matos et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study
- (2018) David R. Gandara et al. Journal of Thoracic Oncology
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- (2018) Roger Sun et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients
- (2018) Taylor J Jensen et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
- (2017) Frédéric Bigot et al. EUROPEAN JOURNAL OF CANCER
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials
- (2017) Dickran Kazandjian et al. SEMINARS IN ONCOLOGY
- Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy
- (2017) Daiki Ogawara et al. Thoracic Cancer
- Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression
- (2017) Georgina V. Long et al. JAMA Oncology
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Report of two cases of pseudoprogression in patients with non–small cell lung cancer treated with nivolumab—including histological analysis of one case after tumor regression
- (2016) Junko Tanizaki et al. LUNG CANCER
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
- (2016) Saby George et al. JAMA Oncology
- Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
- (2016) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma
- (2015) Roberto Iacovelli et al. EUROPEAN UROLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
- (2014) Evan J Lipson et al. Journal for ImmunoTherapy of Cancer
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
- (2011) Ignacio Garrido-Laguna et al. CANCER
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now